Meta-analysis of mRNA dysregulation associated with Parkinson's disease and other neurological disorders
Abstract
Parkinson’s disease (PD) is the second most common progressive neurodegenerative disorder, characterized by both motor and non-motor symptoms. In this study, we conducted a meta-analysis of gene expression profiles from four GEO datasets (comprising 59 PD patients and 41 participants control) to identify consistently differentially expressed messenger ribonucleic acids (DEmRNAs). We identified 5,495 down-regulated and 9,850 up-regulated DEmRNAs, of which 64 and 25, respectively, were common across all datasets. Functional enrichment analysis revealed that down-regulated DEmRNAs were primarily enriched in pathways related to neurotransmitter transport, dopamine biosynthesis, and dopaminergic synapse function, while up-regulated DEmRNAs were linked to cell cycle regulation and PI3K-Akt signaling. Notably, dysregulation of key genes, including SNCA (encoding α-synuclein), SLC6A3, TUBB, TUBB3, TUBB4B, and NDUFA9, were associated with PD as well as other neurodegenerative disorders, such as Alzheimer’s, Huntington’s, and Prion diseases. These DEmRNAs and pathways may offer potential biomarkers and therapeutic targets for PD and related neurological disorders.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 59 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.